

November 2, 2018

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Norio Hamada, Chairman of the Board and Representative Director, Chief Executive Officer (CEO) (First Section of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Director and General Manager, Public and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Contract on Distribution Operation of Haemophilia B Drug  
by Novo Nordisk Pharma Ltd.

TOHO HOLDINGS CO., LTD.(Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada; hereinafter, “TOHO HOLDINGS”) hereby announces, its wholly owned subsidiary TOHO PHARMACEUTICAL CO., LTD.(Headquarters: Tokyo; President and Representative Director: Hiromi Eda; hereinafter, “TOHO PHARMACEUTICAL”) and other Kyoso Mirai Group companies signed a contract on distribution operation of the Haemophilia B treatment drug Refixia® 500 / 1000 / 2000 (hereinafter, “Refixia®”), which was launched by Novo Nordisk Pharma Ltd., (Headquarters: Tokyo; President and Representative Director : Ole Mølskov Bech, hereinafter “Novo Nordisk Pharma”).

1. Contract background

TOHO HOLDINGS, as a corporate group engaged in the medical, health and nursing care sector and under the corporate slogan, “Total commitment to good health”, conducts businesses such as pharmaceutical wholesaling, management of pharmacies, manufacture and sale of pharmaceuticals, development and provision of customer support systems, etc.,.

Novo Nordisk Pharma required refrigerated delivery services and valued TOHO HOLDINGS’s highly-functional logistics system, emergency response system, and contract performance history to launch Refixia® which treats a rare disease called Hemophilia B; therefore, the contract on distribution operation of Refixia® was made. TOHO HOLDINGS employs “SALM” (see photos below) as the delivery box for Refixia® and enables temperature control from delivery to storage at medical institutions.

2. About Refixia®

Refixia® [generic name: Nonacog Beta Pegol (Genetical Recombination)] is an extended half-life factor IX product indicated for regular replacement therapy, on-demand treatment of bleeding episodes, and surgical procedures in patients with Haemophilia B. PEGylation successfully prolonged duration of action, and other pharmacokinetic profiles have also been improved. Refixia® was granted marketing authorization in Japan on July 2, 2018.

3. Performance outlook

Impact to consolidated performance is minor.

■ Refixia® Delivery Box ”SALM”

